Newly public Conexeu (Nasdaq: CNXU) completed a preclinical study for its CXU tissue-restoration platform targeting GLP-1 volume loss. It is not FDA approved.
Conexeu Sciences, newly listed on Nasdaq as CNXU, completed a 12-month preclinical animal study for its CXU tissue-restoration platform, positioning it for the facial and body volume loss that can follow GLP-1 weight loss. CXU is investigational and not FDA cleared. A 510(k) wound-care filing is planned for Q1 2027.
Conexeu Sciences, a preclinical-stage biotech now trading on Nasdaq under the ticker CNXU, is pitching a soft-tissue restoration platform aimed at a gap the weight-loss boom has opened. On July 7, 2026, the Reno, Nevada company said it completed a 12-month preclinical animal study for its CXU platform, framing the roughly $190 billion projected GLP-1 weight-loss market as evidence that today's volumizing injectables were not built to address rapid tissue loss.
The headline claim is a market thesis, not a treatment you can book. CXU and its lead device candidate, Ten-Minute Tissue, are investigational and have not been cleared or approved by the FDA or any regulatory body. Here is what the company has actually done, what remains pending, and why patients navigating GLP-1 related volume loss should read the announcement carefully.
Conexeu announced completion of its 12-month P.R.O.O.F. study (Performance and Regeneration Outcomes of Flowable Collagen), an animal-model evaluation of its CXU platform, a thermosensitive, flowable collagen scaffold that stays liquid at room temperature and is designed to set into a stable gel at body temperature within about ten minutes. The company says the study met tissue-restoration objectives in a small-volume facial (cheek) model and a large-volume, 200cc-equivalent subcutaneous model, and met injectability and volumizing benchmarks. Detailed quantitative data is being reserved for peer-reviewed publication. These are preclinical, animal results; the company states clearly that preclinical results are not necessarily predictive of results in humans.
Nothing here is available to patients today. Approved or cleared: none. CXU and Ten-Minute Tissue are investigational and not FDA cleared or approved for any use. Pending: Conexeu plans a predicate-based 510(k) submission for wound care in early 2027 (Q1 2027), targeting a 90-day FDA review, and intends that clearance to become the foundation for later expansion into medical aesthetics, which would require its own regulatory pathway. By contrast, the products patients actually use for post-weight-loss volume loss today, hyaluronic acid fillers such as Juvederm and Restylane and biostimulators such as poly-L-lactic acid (Sculptra) and calcium hydroxylapatite (Radiesse), are already FDA-approved, though use specifically for GLP-1 related changes is often off-label.
Rapid weight loss on GLP-1 drugs can thin facial fat pads, producing the hollowing widely called Ozempic face, plus laxity elsewhere on the body. Boston Consulting Group data cited in the release projects GLP-1 related aesthetic revenue growing from roughly $0.7 billion in 2025 to $2.0 billion by 2030, which is the demand Conexeu is targeting. For now, that demand is met by existing approved injectables and by clinical judgment on timing, not by CXU. Watch three things: whether the P.R.O.O.F. data is published and peer-reviewed, whether the Q1 2027 wound-care 510(k) is filed and cleared, and whether any aesthetic indication ever enters human trials. Until then, treat CXU as a pipeline story, not a treatment option.